Abstract
Acinetobacter baumannii has been associated with antimicrobial resistance and ability to form biofilms. Furthermore, its adherence to host cells is an important factor to the colonization process. Therefore, this study intended to identify some virulence factors that can explain the success of A. baumannii in causing nosocomial infections. We studied 92 A. baumannii isolates collected from hospitals in Rio de Janeiro, Brazil. Isolates were identified and the susceptibility to antimicrobials was determined. Oxacilinase type β-lactamase encoding genes were amplified by polymerase chain reaction, and genetic diversity was investigated by pulsed-field gel electrophoresis (PFGE). In addition, biofilm formation on polystyrene plates using crystal violet staining was quantified, and adherence to human cell lines was evaluated. Eighty-six isolates were multidrug-resistant, of which 93% were carbapenem-resistant. All isolates had the blaOXA-51 gene and 94% had the blaOXA-23 gene, other searched blaOXA genes were not detected. PFGE typing showed two predominant clones, and biofilm production was observed in 79% of isolates. A. baumannii isolates adhered better to HEp-2 cell compared with A-549 cell. Clones A, B, E, and F showed a significantly increased adherence to HEp-2 compared with adherence to A-549 cell. Our findings revealed that A. baumannii isolates had high frequencies of resistance to antimicrobial agents, ability to form biofilm, and capacity to adhere to HEp-2 cells.
Keywords: Acinetobacter baumannii, Antimicrobial resistance, PCR, PFGE, Biofilm, Adherence to cell
Introduction
Acinetobacter baumannii is an aerobic, non-fermentative Gram-negative coccobacillus that can survive for long periods in the environment [1]. A. baumannii infections are a major cause of hospital-acquired infections worldwide, mainly due to A. baumannii’s ability to live under critical situations in this environment [2, 3]. Resistance to desiccation and antibiotics [4, 5], high production of biofilm on abiotic surfaces, and the adherence to human cells [6–9] might justify the prevalence of this microorganism in hospitals in outbreaks and endemic situations.
Extensive use of antibiotics in hospitals has contributed to the rapid appearance of resistant A. baumannii isolates [10]. Carbapenems are widely used to treat infections caused by MDR A. baumannii, but increasing resistance to carbapenems in A. baumannii infections in the past decade has been creating therapeutic challenges [11]. Carbapenem resistance in A. baumannii is generally associated to the oxacillinase (OXA) enzyme group. Among the phylogenetic subgroups of OXA already identified, six were described in A. baumannii: OXA-23-like, OXA-24-like, OXA-51-like, OXA-58-like, OXA-143-like, and OXA-235-like [12–14].
In Brazil, the first report of carbapenem-resistant A. baumannii isolates was in 2003 with the description of OXA-23–producing A. baumannii belonging to a single clone [15]. In 2009, Carvalho et al. (2009) described the spread of two predominant clones of MDR OXA-23–producing A. baumannii in the city of Rio de Janeiro [16]. However, another study done in the same city demonstrated no predominant clones and distribution of the blaOXA-23 gene in several clones analyzed [17].
There are few papers on the virulence-associated factors of A. baumannii [18]. Biofilm formation plays a significant role in the pathogenicity of this microorganism and is associated with increased bacterial survival [19]. Bacteria in biofilms are more resistant to antimicrobial agents when compared with planktonic cells [20]. Moreover, biofilm allows bacteria to persist on biotic and abiotic surfaces and helps them to evade the host response. The ability of bacteria to adhere to eukaryotic cells is critical for pathogenesis and generally considered an essential early step in the colonization process, and the biofilm formation and its adherence to cells are common features in clinical A. baumannii isolates [21, 22].
The features that make A. baumannii able to induce outbreaks and human diseases are not totally understood. Therefore, this study intended to identify some virulence factors present in A. baumannii isolates obtained from patients with nosocomial infections. To this purpose, we characterized the antimicrobial resistance, clonal relationships, biofilm formation, adherence, and invasion to eukaryotic cells ability of 92 Acinetobacter baumannii isolates from two public hospitals in Rio de Janeiro, Brazil.
Material and methods
Bacterial isolates
Ninety-two clinical Acinetobacter baumannii isolates collected from two public hospitals in the city of Rio de Janeiro, between 2010 and 2011, were included in this study. A. baumannii isolates were identified by automated VITEK 2 System (bioMérieux Vitek Systems Inc., Hazelwood, MO, CA) and by partial rpoB sequencing [23]. The sources of isolates collected included urine, blood, catheter, tracheal secretion, and wound and bronchoalveolar lavage. In an earlier study, we described molecular identification, sources, and antimicrobial susceptibility for polymyxin B by minimum inhibition concentration (MIC) of these isolates [24].
Antimicrobial susceptibility testing
To evaluate the antimicrobial susceptibility of the isolates, the automated VITEK 2 System (bioMérieux Vitek Systems, Inc., Hazelwood, MO) was used with a Gram-negative identification card (NG-105) following the manufacturer’s instructions. The following antibiotics were tested: amikacin, gentamicin, ampicillin-sulbactam, piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, ciprofloxacin, imipenem, and meropenem. Values were interpreted according to the guidelines of CLSI [25], and isolates were classified as non-multidrug-resistant (n-MDR) and multidrug-resistant (MDR) according to the criteria of Magiorakos et al. (2012) [26].
Oxacillinases detection
The genomic DNA was extracted using DNeasy Tissue Kit (QIAGEN, Valencia, CA), according to manufacturer’s instructions. Multiplex-PCR reactions using specific primers for amplifying blaOXA-23, blaOXA-24, blaOXA-51,blaOXA-58, and blaOXA-143 genes were done as described previously by Woodford et al. (2006) and Higgins et al.(2010) [27, 28]. For the blaOXA-23 and blaOXA-51 positive isolates, new PCR reactions were performed [29, 30]. The PCR products were purified using PureLink PCR purification Kit (Invitrogen) and sequenced using BigDye Terminator Cycle Sequencing Kit (Applied Biosystems). Sequences were analyzed using DNASTAR software, and subsequently, the obtained sequences were submitted to BLAST (Basic Local Alignment Search Tool) [2].
Pulsed-field gel electrophoresis (PFGE)
Isolates were typed by PFGE [31] following digestion of genomic DNA with Apa I (Invitrogen). DNA fragments were separated on 1% (w/v) agarose gels in 0.5% TBE [Tris–borate–ethylene diamine tetra-acetic acid (EDTA)] buffer using a CHEF-DR III apparatus (Bio-Rad, Hercules, CA) with 6 V/cm, pulsed from 5 to 15 s, for 18 h at 14 °C. Gels were stained with ethidium bromide and photographed under ultraviolet light. The Apa I restriction profiles were initially compared by visual inspection according to the criteria of Tenover et al. (1995) [32]. Computer-assisted analysis was also performed using BioNumerics v.4.0 (Applied Maths, Sint-Martens-Latem, Belgium). Comparison of the banding patterns was accomplished by the unweighted pair group method with arithmetic averages (UPGMA) using the Dice similarity coefficient.
Quantification of biofilm formation
The biofilm formation was performed in 96-well microplates of polystyrene assay (Nunclon ™ – Nalgene Nunc International, Rochester, NY Catalog No. 269 787), using an overnight culture, according to Moskowitz et al. (2004) [33]. Each strain was tested in triplicate. We used the A. baumannii ATCC 19606 type strain as positive control. Wells with culture medium not inoculated were considered as negative control and Escherichia coli K-12 isolate weakly biofilm producing. All tests were performed in triplicate and the results were averaged. The biofilm formation was graded as described by Stepanovic et al. (2000) [34].
Eukaryotic cell culture
Human alveolar epithelial tumor cells A-549 and human epithelial laryngeal carcinoma cells (HEp-2) were obtained from the American Type Culture Collection. The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 1% of penicillin, 1% of streptomycin, and 10% fetal bovine serum at 37 °C in 5% CO2. Confluent growth was obtained in 100 mm diameter in 24-well plates (Nunclon™ – Nalgene Nunc International, Rochester, NY).
Bacterial adherence assays
The adherence assays of A. baumannii isolates to eukaryotic cells were determined as described previously with some modifications [7]. Strains of A. baumannii were cultured in 10 mL of nutrient agar at 37 °C for 24 h. Bacterial suspensions were washed and adjusted to match the turbidity standard of 2 McFarland units (approximately 6.0 × 108 CFU/mL) in DMEM. The adherence assays were conducted by exposing eukaryotic cells at a multiplicity of infection (MOI, bacterium: eukaryotic cell ration) ~ 50:4 of A. baumannii isolates. The infected plates were centrifuged for 10 min at 700 ×g prior to the incubation to promote adherence of bacteria to cells and to synchronize infections. Each strain was tested in triplicate and experiments were performed in duplicate. After 2 h of incubation at 37 °C, the coverslips were washed, and the cells fixed and stained with Giemsa solution for 30 min. The coverslips were placed on glass slides. Bacterial adherence to the cells was determined by optical microscopy. In each field displayed on the optical microscope, bacteria that have adhered to human epithelial cells were counted. For each coverslip, 300 ± 45 cells were inspected to determine the number of adhered bacteria [9, 35]. Two independent experiments were performed with two coverslips each. A. baumannii ATCC 19606 was included in each test series as a reference strain.
Bacterial invasion assay
For quantification of adherent bacteria, the cells were plated in 24-well plates (Nunclon™ – Nalgene Nunc International, Rochester, NY) without glass coverslips. The cells grown in plates were infected with A. baumannii isolates under the same conditions as those described for bacterial adherence assays. After the period of 2 h incubation, we added 250 μg/ml of polymyxin B to the wells to kill any extracellular bacteria. After this time, the wells were washed with PBS, and the cells were lysed with Triton X-100 in 0.1X PBS 1X for 20 min at 37 °C in 5% CO2. The CFU was determined by successive dilution in 0.85% saline and plated on MacConkey agar. The Yersinia enterocolitica O:3 isolate was used as positive control for bacterial invasion [8]. Two independent experiments were performed.
Cell viability by the tetrazolium reduction assay
In addition to the bacterial invasion assay, we evaluated the cell viability of HEp-2 cell following exposure to A. baumannii isolates by the tetrazolium reduction assay [36], which was performed in a 96-well microtiter plate (Corning Costar® Sigma-Aldrich, catalog No. 32190102). After incubation of the confluent monolayers of cells HEp-2 previously infected with 10 μL (~ 106 CFU) of A. baumannii isolates for 2 h, 20 μl of the complete DMEM medium were removed and 20 μl of MTT (0.2 mg/ml) were added to each well. Then the cells were incubated for 4 h at 37 °C in 5% CO2, and after which, 20 μl of sodium dodecyl sulfate 10% (SDS, GE Healthcare, Uppsala, Sweden) was added. The absorbance was read in spectrophotometer at 590 nm [37]. Cell viability in infected cultures was calculated considering the absorbance values of negative control as 100%. Two independent experiments were carried out in duplicate.
Statistical analysis
Data obtained in quantification of biofilm formation and cell viability by MTT were analyzed for statistical significance using Grubb’s test. The p value < 0.05 was considered significant.
Student’s t test was used to determine the differences in the percentage of cell viability infected with A. baumannii ATCC 19606 type strain and the selected isolates. Mann–Whitney test was used to determine the differences in the number of bacteria that adhered to A-549 or HEp-2 cells.
Results
Distribution of isolates and antimicrobial resistance
A total of 92 isolates of A. baumannii were collected from two hospitals in Rio de Janeiro (Brazil). Resistance and intermediate resistance to cefotaxime was the most common (87, 94.6%), followed by piperacillin/tazobactam (85, 92.4%), cefepime and ciprofloxacin (83, 90.2%), carbapenems (80, 87%), ceftazidime (77, 83.7%), ampicillin/sulbactam (76, 82.6%), and gentamicin (53, 57.6%). High percentage susceptibility was observed for amikacin (19, 20.7%). Thirteen isolates were resistant to all of the 10 antibiotics. Only 6 isolates were classified as n-MDR, and all of them were susceptible to carbapenems. Most of the isolates that showed resistance to carbapenems were collected from tracheal aspirates (23%, n = 18).
Oxacillinases encoding genes
Using multiplex-PCR, all isolates were positive for the blaOXA-51 gene, and 85 isolates (92%) were positive for blaOXA-23.The sequences were submitted to BLAST and similarity values > 99% were found among all. No isolate was positive for blaOXA-24, blaOXA-58, or blaOXA-143 genes.
PFGE typing
According to Tenover’s criteria [32], the PFGE analysis revealed 22 clones among the 92 isolates, with a similarity > 85% [38]. Clone A (30% of isolates; n = 28) was the predominant, followed by clone B (19% of isolates; n = 17). Forty-seven of the total 92 A. baumannii isolates were classified in 20 sporadic clones named from C to U, which included at least one isolate of each profile (Fig. 1). Clones A, B, and C were present in both hospitals, whereas others were present in only one of them. The isolates belonged to the predominant clones A and B were mainly collected from tracheal aspirates (24% and 41%, respectively). The majority of n-MDR isolates was grouped only in sporadic clones (S, Q, R, F, V), only one n-MDR A. baumannii isolate belonged to the predominant clone A.
Fig. 1.
Dendrogram of A. baumannii isolates, built with GelCompar II version 4.0 (Applied Maths). Pulsed-field gel electrophoresis (PFGE) detected the patterns of bands after digestion of chromosomal DNA with restriction endonuclease Apa I
Biofilm formation
The quantification of biofilm formation assay showed that 39 isolates were considered strongly adherent (42%), 26 isolates were moderately adherent (28%), and 8 isolates were weakly adherent (9%). Nineteen isolates were considered non-biofilm producers. Most isolates that were considered strongly adherent were collected from wound (58%, n = 7), tracheal aspirates (58%, n = 11), and catheter (53%, n = 15).
Cell adherence assay
Two distinct eukaryotic cells were used to examine adherence of six A. baumannii isolates (Figs. 2 and 3). All isolates were selected as MDR, carbapenem resistant and biofilm producers. Four isolates were considered strongly adherent, and the other two were considered moderately adherent (30,654, clone F) and weakly adherent (33,677, clone A). Verification of the ability of differing clones to adhere to the eukaryotic cells revealed no clonal specific trends. Clones A, B, E, and F showed a significantly increased (p > 0.05) adherence to HEp-2 when compared with A-549 cells. For the other isolates (clones C and D), there was no statistical significance.
Fig. 2.
A-549 cells infected for 2 h with A. baumannii stained and photographed in an optical microscope at a 40x magnification. a Clone A. b Clone B. c Clone C. d Clone D. e Clone E. f Clone F
Fig. 3.
HEp-2 cells infected for 2 h with A. baumannii stained and photographed in an optical microscope at a × 40 magnification. a Clone A. b Clone B. c Clone C. d Clone D. e Clone E. f Clone F
All A. baumannii isolates studied and the A. baumannii ATCC 19606 type strain were not able to invade HEp-2 cells. Y. enterocolitica O:3, used as positive control for bacterial invasion, was able to grow after plating in MacConkey agar (0.5 × 103 CFU/mL).
HEp-2 cells were examined by MTT-assay to determine the viability after infection with A. baumannii isolates. Cells infected by the A. baumannii ATCC 19606 type strain showed 45% cell viability and by clones A, B, C, D, E, and F exhibited 22%, 19%, 38%, 80%, 36%, and 20% cell viability, respectively. After infection, all isolates, except clone C and D, induced a significant decrease in HEp-2 cell viability (p < 0.05) compared with the HEp-2 cell viability after infection by the type strain.
Discussion
Antibiotic resistance and persistence in hospital environments are the two factors that most contribute to the success of A. baumannii as an opportunistic pathogen. However, it is possible that the emergence of isolates over others is the result of their different individual characteristics that allow colonization and disease. Biofilm formation and its adherence to eukaryotic cells were studied as potential virulence-related characteristics among A. baumannii isolates.
Our data show high predominance of MDR A. baumannii and high susceptibility to amikacin, as observed previously [37]. Carbapenems were used to be one of the last resorts when treating resistant Acinetobacter infections, but today high resistance to them is reported. While in 2001 isolates collected in Brazil exhibited only 10% of resistance [39], recently this resistance has increased dramatically [8, 10, 40]. In general, the A. baumannii carbapenem-resistant isolates evaluated here were also resistant to other antimicrobial agents, except to polymyxin B. However, the intensive use of polymyxins has selected resistant isolates, and this has already been shown in Spain, Korea, Iran, USA, and Brazil [24, 40–44].
Different mechanisms are involved in the A. baumannii resistance to carbapenems, but the β-lactamase production is the most important factor [29]. Our study found that the blaOXA-51 gene was the sole carbapenemase gene detected in all the isolates, as expected [45]. The blaOXA-23 gene appeared in most A. baumannii isolates. These data may indicate that carbapenem resistance of isolates most often mediate by oxacillinases like blaOXA-23 gene [46]. Moreover, we also observed the blaOXA-23 gene in carbapenem-susceptible isolates. These results suggest the importance of the occurrence of the silent carriage blaOXA-23 gene in hospital environments and the detection of isolates as reservoir oxacillinase genes [46]. Previously, Carvalho et al. (2011) described that this susceptibility occurs due to different associations between the blaOXA-23 and ISAba1 genes [46]. With regard to blaOXA-24, blaOXA-58, and blaOXA-143 genes, in this study, no Acinetobacter isolate was positive, although international epidemiologic studies have indicated that these oxacillinases are spread among A. baumannii clinical isolates [47].
Various genotyping methods have been used to facilitate the understanding of the epidemiology of an A. baumannii infection [26]. PFGE typing showed two main clones, indicating clonal dissemination. A high prevalence of clones A and B in the studied hospitals showed that health professionals should be very careful to prevent the spread of these clones. Isolates positive for the blaOXA-23 gene were associated with predominant and sporadic clones, unlike a previous study that found the presence of this gene only in few distinct clones [17, 48]. These findings show the diversity of clinical A. baumannii isolates circulating in Rio de Janeiro.
The ability of A. baumannii to persist in hospital environments could be attributed to its ability to form biofilm on abiotic surfaces. Our data show that A. baumannii isolates have different abilities to attach to polystyrene microplates. Previously, Rodríguez-Baño et al. (2008) showed that the ability to form biofilms on abiotic surfaces is common in A. baumannii isolates and that one of the most frequent sites of collection of these isolates is related to the catheter [22]. But in this same study, a higher biofilm formation was also observed in isolates collected from bloodstream infection; these data differ from our study [22].We observed that the MDR isolates were not significantly strong biofilm-forming, since carbapenem-susceptible isolates produced more biofilm than resistant isolates, as observed before [19, 20, 47]. No difference has been verified regarding biofilm-forming capacity between predominant and sporadic clones. Previous reports also did not describe a significant relationship between biofilm formation and PFGE clones [48–50]. Multiple factors contribute to A. baumannii virulence and pathogenicity. The diversity of virulence characteristics among A. baumannii isolates has been previously shown [49, 50], but little information exists about A. baumannii adhesion to eukaryotic cells. The bacterial adhesion assay demonstrated that A. baumannii clones differ in their abilities to adhere to A-549 and HEp-2 cells [7, 9, 51]. Moreover, the isolate belonging to clone F was not able to form strong biofilm in polystyrene microplates, but was able to adhere better to the HEp-2 cells. The non-correlation of biofilm formation on abiotic and biotic surfaces indicates that different mechanisms are involved in these colonization processes, such as the participation of structures such as pili, associated only with biofilm formation on abiotic surfaces [52]. In addition, the isolates belonging to the major PFGE clones (A and B) did not adhere to eukaryotic cells more than others [7]. The optical microscopy analyses also suggest that bacteria can adhere but not invade eukaryotic cells, and this was consistent with the invasiveness experiment performed. Reports indicate that A. baumannii infection leads to apoptotic death without invasion of the pathogen [8, 53]. Cell viability by the MTT reduction assay showed consistent data with that observed in optical microscopy. However, the isolates belonging to A and B clones induced significant decrease in the viability of HEp-2 cells, which was not observed in optical microscopy.
In summary, the results presented in this study showed the ability of the A. baumannii clinical isolates to form biofilm and attach to eukaryotic cells. Furthermore, we indicated individual differences among the isolates, irrespective of their belonging to the predominant or sporadic clones, mainly in relation to biofilm formation and adherence to epithelial cells.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol. 2008;21:538–582. doi: 10.1128/CMR.00058-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Dai N, Li DZ, Chen JC, Chen YS, Geng R, Hu YH, Zhang W, Li JS, Yu Q, Wan HY, Mu L, Zhong XN, Wei LP, Ma JJ, Wang QY, Hu K, Tian GZ, Cai SX, Wang RQ, He B, Wang SQ, Wang ZW, Zhao SR, Gao ZC. Drug-resistant genes carried by Acinetobacter baumannii isolated from patients with lower respiratory tract infection. Chin Med J (Engl) 2010;123:2571–2575. doi: 10.1155/2017/7157923. [DOI] [PubMed] [Google Scholar]
- 3.Sieniawski K, Kaczka K, Rucińska M, Gagis L, Pomorski L. Acinetobacter baumannii nosocomial infections. Pol Przegl Chir. 2013;85:483–490. doi: 10.2478/pjs-2013-0075. [DOI] [PubMed] [Google Scholar]
- 4.Webster C, Towner KJ, Humphreys H. Survival of Acinetobacter on three clinically related inanimate surfaces. Infect Control Hosp Epidemiol. 2000;21:246. doi: 10.1086/503214. [DOI] [PubMed] [Google Scholar]
- 5.Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. 2011;3:1055–1060. doi: 10.1002/iub.533. [DOI] [PubMed] [Google Scholar]
- 6.Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiol. 2003;149:3473–3484. doi: 10.1099/mic.0.26541-0. [DOI] [PubMed] [Google Scholar]
- 7.Lee JC, Koerten H, van den Broek P, Beekhuizen H, Wolterbeek R, van den Barselaar M, van der Reijden T, van der Meer J, van de Gevel J, Dijkshoorn L. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol. 2006;157:360–366. doi: 10.1016/j.resmic.2005.09.011. [DOI] [PubMed] [Google Scholar]
- 8.Choi CH, Lee JS, Lee YC, Park TI, Lee JC. Acinetobacter baumannii invades epithelial cells and outer membrane protein a mediates interactions with epithelial cells. BMC Microbiol. 2008;8:216. doi: 10.1186/1471-2180-8-216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lee HW, Koh YM, Kim J, Lee JC, Lee YC, Seol SY, Cho DT, Kim J. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect. 2008;14:49–54. doi: 10.1111/j.1469-0691.2007.01842. [DOI] [PubMed] [Google Scholar]
- 10.Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, Gordon SM. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia between intubated patients. Chest. 1999;115:1378–1382. doi: 10.1378/chest.115.5.1378. [DOI] [PubMed] [Google Scholar]
- 11.Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2008;52:570–573. doi: 10.1099/jmm.0.025668-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother. 2010;54:24–38. doi: 10.1128/AAC.01512-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Higgins PG, Pérez-LlarenaFJ ZE, FernándezA BG, Seifert H. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:2121–2126. doi: 10.1128/AAC.02413-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Higgins PG, PoirelL LM, NordmannP SH. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009;53:5035–5038. doi: 10.1128/AAC.00856-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo KL, Rea-Neto A, Penteado-Filho SR, Livermore DM, Woodford N. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol. 2003;41:3403–3406. doi: 10.1128/JCM.41.7.3403-3406.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Carvalho KR, Carvalho-Assef AP, Santos LG, Pereira MJ, Asensi MD. Occurrence of blaOXA-23 gene in imipenem-susceptible Acinetobacter baumannii. Mem Inst Oswaldo Cruz. 2011;106:505–506. doi: 10.1590/S0074-02762011000400020. [DOI] [PubMed] [Google Scholar]
- 17.Fonseca EL, Scheidegger E, Freitas FS, Cipriano R, Vicente AC. Carbapenem-resistant Acinetobacter baumannii from Brazil: role of carO alleles expression and blaOXA-23 gene. BMC Microbiol. 2013;13:245. doi: 10.1186/1471-2180-13-245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.de Breij A, Dijkshoorn L, Lagendijk E, van der Meer J, Koster A, Bloemberg G, Wolterbeek R, van den Broek P, Nibbering P. Do biofilm formation and interactions with human cells explain the clinical success of Acinetobacter baumannii? PLoS One. 2010;59:e10732. doi: 10.1371/journal.pone.0010732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol. 2013;37:130–135. doi: 10.1111/j.1574-6976.2012.00344.x. [DOI] [PubMed] [Google Scholar]
- 20.Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108. doi: 10.1038/nrmicro821. [DOI] [PubMed] [Google Scholar]
- 21.Beachey EH, Giampapa CS, Abraham SN. Bacterial adherence: Adhesin receptor-mediated attachment of pathogenic bacteria to mucosal surfaces. Am Ver Respir Dis. 1988;138:S45–S48. doi: 10.1093/infdis/143.3.325. [DOI] [PubMed] [Google Scholar]
- 22.Rodriguez-Baño J, Marti S, Soto S, Fernandez-Cuenca F, Cisneros JM, Pachon J, Pascual A, Martínez-Martínez L, McQueary C, Actis LA, Vila J. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infect. 2008;14:276–278. doi: 10.1111/j.1469-0691.2007.01916.x. [DOI] [PubMed] [Google Scholar]
- 23.La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006;44:827–832. doi: 10.1128/JCM.44.3.827-832.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Genteluci GL, Gomes DBC, de Souza MJ, Carvalho KR, Villas-Bôas MHS. Emergence of polymyxin B-resistant Acinetobacter baumannii in hospitals in Rio de Janeiro. J Bras Patol Med Lab. 2016;52:91–95. doi: 10.1038/s41426-018-0127-9. [DOI] [Google Scholar]
- 25.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S25. Wayne, Pennsylvania: CLSI; 2015
- 26.Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x. [DOI] [PubMed] [Google Scholar]
- 27.Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Inter J Antimicrob Agent. 2006;27:351–353. doi: 10.1016/j.ijantimicag.2009.10.014. [DOI] [PubMed] [Google Scholar]
- 28.Higgins PG, Lehmann M, Seifert H. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2010;35:305–314. doi: 10.1016/j.ijantimicag.2009.10.014. [DOI] [PubMed] [Google Scholar]
- 29.Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D -lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2001;45:583–588. doi: 10.1074/mcp.M115.051052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258:72–77. doi: 10.1111/j.1574-6968.2006.00195.x. [DOI] [PubMed] [Google Scholar]
- 31.Romão CM, Faria YN, Pereira LR, Asensi MD. Susceptibility of clinical isolates of multiresistant Pseudomonas aeruginosa to a hospital disinfectant and molecular typing. Mem Inst Oswaldo Cruz. 2005;100:541–548. doi: 10.1590/S0074-02762005000500015. [DOI] [PubMed] [Google Scholar]
- 32.Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–2239. doi: 10.1128/JCM.33.9.2233-2239.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolate of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–1922. doi: 10.1128/JCM.42.5.1915-1922.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Stepanovic S, Vukovic D, Dakic I, Savic B. Svabic-Vlahovic M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000;40:175–179. doi: 10.1016/S0167-7012(00)00122-6. [DOI] [PubMed] [Google Scholar]
- 35.Silva CA, Danelishvili L, McNamara M, Berredo-Pinho M, Bildfell R, Biet F, Rodrigues LS, Oliveira AV, Bermudez LE, Pessolani MC. Interaction of Mycobacterium leprae with human airway epithelial cells: adherence, entry, survival, and identification of potential adhesins by surface proteome analysis. Infect Immun. 2013;81:2645–2659. doi: 10.1128/IAI.00147-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sieuwerts AM, Klijn JG, Peters HA, Foekens JA. The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem. 1995;33:813–823. doi: 10.1515/cclm.1995.33.11.813. [DOI] [PubMed] [Google Scholar]
- 37.Chagas TP, Carvalho KR, de Oliveira Santos IC, Carvalho-Assef AP, Asensi MD. Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008-2011): countrywide spread of OXA-23-producing clones (CC15 and CC79) Diagn Microbiol Infect Dis. 2014;79:468–472. doi: 10.1016/j.diagmicrobio.2014.03.006. [DOI] [PubMed] [Google Scholar]
- 38.Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B, Stefanik D, Heersma H, Dijkshoorn L. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol. 2005;43:4328–4335. doi: 10.1128/JCM.43.9.4328-4335.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Viana GF, dos Santos Saalfeld SM, Garcia LB, Cardoso CL, Pelisson M, Tognim MC. Evolution of antimicrobial resistance of Acinetobacter baumannii in a university hospital. Lett Appl Microbiol. 2011;53:374–378. doi: 10.1111/j.1472-765X.2011.03109.x. [DOI] [PubMed] [Google Scholar]
- 40.Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:1163–1167. doi: 10.1093/jac/dkm305. [DOI] [PubMed] [Google Scholar]
- 41.Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother. 2009;53:1295–1296. doi: 10.1128/AAC.01097-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bahador A, Taheri M, Pourakbari B, Hashemizadeh Z, Rostami H, Mansoori N, Raoofian R. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel international clone variants. Microb Drug Resist. 2013;19:397–406. doi: 10.1089/mdr.2012.0233. [DOI] [PubMed] [Google Scholar]
- 43.Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208:1142–1151. doi: 10.1093/infdis/jit293. [DOI] [PubMed] [Google Scholar]
- 44.Gomes DBC, Genteluci GL, Carvalho KR, Medeiros LM, Almeida VC, de Castro EAR, Villas-Bôas MHS. Acinetobacter baumannii multirresistentes: emergência de resistência à polimixina no Rio de Janeiro. Vigil Sanit Debate. 2016;4:28–34. doi: 10.22239/2317-269X.00732. [DOI] [Google Scholar]
- 45.Evans BA, Hamouda A, Towner KJ, SGB A. OXA-51-like β-lactamases and their association with particular epidemic lineages of Acinetobacter baumannii. Clin Microbiol Infect. 2008;14:268–275. doi: 10.1111/j.1469-0691.2007.01919. [DOI] [PubMed] [Google Scholar]
- 46.Carvalho KR, Carvalho-Assef APD, Peirano G, Santos LC, Pereira MJ, Asensi MD. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying blaOXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents. 2009;34:25–28. doi: 10.1016/j.ijantimicag.2008.12.009. [DOI] [PubMed] [Google Scholar]
- 47.Schimith-Bier KE, LuizSO SMC, GalesAC PMC, Nascimento AJ, Carignano E, Dalla Costa LM. Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil. Am J Infect Control. 2010;38:308–314. doi: 10.1016/j.ajic.2009.09.012. [DOI] [PubMed] [Google Scholar]
- 48.Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, Prashanth K. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J Med Microbiol. 2008;26:333–337. doi: 10.4103/0255-0857.43566. [DOI] [PubMed] [Google Scholar]
- 49.Qi L, Li H, Zhang C, Liang B, Li J, Wang L, Du X, Liu X, Qiu S, Song H. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol. 2016;7:483. doi: 10.3389/fmicb.2016.00483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Ali HM, Salem MZM, El-Shikh MS, Megeed AA, Alogaibi YA, Talea IA. Investigation of the virulence factors and molecular characterization of the clonal relations of multidrug-resistant Acinetobacter baumannii isolates. J AOAC Int. 2017;100:152–158. doi: 10.5740/jaoacint.16-0139. [DOI] [PubMed] [Google Scholar]
- 51.Rumbo C, Tomás M, Fernández Moreira E, Soares NC, Carvajal M, Santillana E, Beceiro A, Romero A, Bou G. The Acinetobacter baumannii Omp33-36 porin is a virulence factor that induces apoptosis and modulates autophagy in human cells. Infect Immun. 2014;82:4666–4680. doi: 10.1128/IAI.02034-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.de Breij A, Gaddy J, van der Meer J, Koning R, Koster A, van den Broek P, Actis L, Nibbering P, Dijkshoorn L. CsuA/BABCDE-dependent pili are not involved in the adherence of Acinetobacter baumannii ATCC19606(T) to human airway epithelial cells and their inflammatory response. Res Microbiol. 2009;60:213–219. doi: 10.1016/j.resmic.2009.01.002. [DOI] [PubMed] [Google Scholar]
- 53.Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16:91–102. doi: 10.1038/nrmicro.2017.148. [DOI] [PMC free article] [PubMed] [Google Scholar]



